Invesco’s LENZ Therapeutics LENZ Stock Holding History

Invesco’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75.3K	Sell	13,256 -1,671	-11%	-$13.5K	﹤0.01%	3766
2026 Q1	$137K	Buy	14,927 +881	+6%	+$12.4K	﹤0.01%	3583
2025 Q4	$225K	Sell	14,046 -350,219	-96%	-$10.2M	﹤0.01%	3487
2025 Q3	$17M	Buy	364,265 +97,585	+37%	+$3.59M	﹤0.01%	1534
2025 Q2	$7.82M	Buy	+266,680	New	+$7.25M	﹤0.01%	1937
2024 Q1	–	Sell	-1,917	Closed	-$35.2K	–	3952
2023 Q4	$35.2K	Buy	1,917 +234	+14%	+$3.86K	﹤0.01%	3780
2023 Q3	$29.2K	Buy	1,683 +4	+0.2%	+$70	﹤0.01%	3834
2023 Q2	$30.6K	Buy	+1,679	New	+$33.5K	﹤0.01%	3847

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Invesco's LENZ Position: Q2 2026 in Review

Invesco reduced its LENZ Therapeutics (LENZ) stake by 11% in Q2 2026, selling an estimated $13.5K and leaving 13,256 shares worth $75.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3766.

Invesco first reported a position in LENZ in Q2 2023 and has held it in 8 quarters since. The position peaked at $17M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Invesco held 13,256 shares of LENZ Therapeutics worth $75.3K as of Q2 2026.
Invesco sold 1,671 LENZ Therapeutics shares in Q2 2026, an estimated $13.5K.
LENZ Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3766 holding.
Invesco first reported a position in LENZ Therapeutics in Q2 2023 and has held it in 8 quarters since.
Invesco's LENZ Therapeutics position peaked at $17M in Q3 2025.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.